Showing results (1731-1740 of 1,962) with videos related to

Sort By:
Pageof 197
Nederlands Tijdschrift Voor Geneeskunde|February 23, 2010
[Improved compliance with the 'Melanoma' treatment guideline]Laetitia Veerbeek, Lonneke V van de Poll-Franse, Marcel W Bekkenk, et al.
Neuroimage. Clinical|June 25, 2023
The association of prediabetes and type 2 diabetes with hippocampal subfields volume: The Maastricht studyJennifer Monereo-Sánchez, Jacobus F A Jansen, Sebastian Köhler, et al.
Biomacromolecules|July 13, 2017
Next Generation Hemostatic Materials Based on NHS-Ester Functionalized Poly(2-oxazoline)sMarcel A Boerman, Edwin Roozen, María José Sánchez-Fernández, et al.
Tissue Engineering. Part A|May 14, 2014
Tuning the degradation rate of calcium phosphate cements by incorporating mixtures of polylactic-co-glycolic acid microspheres and glucono-delta-lactone microparticlesKemal Sariibrahimoglu, Jie An, Bart A J A van Oirschot, et al.
Diabetologia|September 16, 2022
Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht StudyPomme I H G Simons, Olivier Valkenburg, Marjo P H van de Waarenburg, et al.
Neuroimage. Clinical|July 24, 2018
High field imaging of large-scale neurotransmitter networks: Proof of concept and initial application to epilepsyTamar M van Veenendaal, Walter H Backes, Desmond H Y Tse, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 12, 2018
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individualsM J Bakker-Huvenaars, C U Greven, P Herpers, et al.
Neuroimage. Clinical|October 14, 2020
CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic reviewWhitney M Freeze, Merel van der Thiel, Jeroen de Bresser, et al.
The Lancet. Rheumatology|October 2, 2020
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialViola Klück, Tim L Th A Jansen, Matthijs Janssen, et al.
The Journal of Rheumatology|August 3, 2016
Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM RegistrySofie H M Manders, Wietske Kievit, Tim L T A Jansen, et al.
Pageof 197